Carcinoid Tumor Market Research Reveals Path To $2.88 Billion By 2030

The carcinoid tumor market is poised for substantial growth in the coming years, driven by advancements in treatment options and diagnostics. As research intensifies and personalized therapies become more prevalent, this specialized oncology segment is attracting significant attention from pharmaceutical companies and healthcare providers alike. Below is an overview of the current market size, key players, emerging trends, and segmentation details shaping this field.

Projected Market Valuation and Growth Outlook for the Carcinoid Tumor Industry
By 2030, the carcinoid tumor market is expected to reach a valuation of $2.88 billion, expanding at a compound annual growth rate (CAGR) of 10.1%. This robust growth stems from several factors, including the surge in the development of new targeted therapies, increased investments dedicated to rare cancer research, and the broader adoption of precision oncology methods. Personalized treatment regimens and an emphasis on improving patients' quality of life also play an important role. Key trends anticipated to influence this market include a growing preference for targeted neuroendocrine tumor therapies, the rising use of combination drug treatments, enhanced focus on early tumor detection, the expansion of specialized cancer treatment centers, and continuous efforts toward long-term disease management.

The carcinoid tumor market size has grown rapidly in recent years. It will grow from $1.77 billion in 2025 to $1.96 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to improved awareness of rare cancers, expansion of oncology care facilities, availability of somatostatin analog therapies, growth of cancer specialty clinics, advancements in neuroendocrine tumor research.

Download a free sample of the carcinoid tumor market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Important Drivers Behind Market Expansion in the Carcinoid Tumor Field
One major factor propelling the carcinoid tumor market forward is the advancement and increased availability of novel, targeted therapies. These treatments offer more precise options for managing neuroendocrine tumors and improving patient outcomes, encouraging wider adoption among oncologists and healthcare providers.
Additionally, there is growing investment in rare cancer research, which supports the development of innovative therapies and diagnostic tools. As cancers like carcinoid tumors receive more attention in the medical research community, breakthroughs are becoming more frequent, positively impacting the market's growth trajectory.

Leading Players Influencing the Carcinoid Tumor Market Landscape
The carcinoid tumor market features a number of prominent pharmaceutical and biotech companies actively engaged in research, development, and commercialization of treatments. Key participants include Novartis AG, Ipsen SA, Pfizer Inc, Merck & Co Inc, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Bristol Myers Squibb, Amgen Inc, Takeda Pharmaceutical Company, Bayer AG, Exelixis Inc, Lexicon Pharmaceuticals Inc, HUTCHMED, Crinetics Pharmaceuticals, Clovis Oncology, Taiho Pharmaceutical, Eisai Co Ltd, and Teva Pharmaceutical Industries.
Notably, in March 2024, Merck enhanced its oncology portfolio by acquiring Harpoon Therapeutics, Inc., a biopharmaceutical firm specializing in next-generation T-cell engagers for solid tumor treatments. This strategic acquisition aims to accelerate Merck's development of innovative immuno-oncology therapies and strengthen its position in targeted cancer treatment.

View the full carcinoid tumor market report:
https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends and Opportunities within the Carcinoid Tumor Sector
Companies in this sector are prioritizing advancements in diagnostic technology to improve early detection and treatment outcomes. A key innovation is the fully automated chromogranin A (CgA) test, which measures a critical biomarker for neuroendocrine tumors such as carcinoid tumors.
For example, in October 2023, Thermo Fisher Scientific Inc., a US-based biotech firm, gained FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This assay is the first FDA-approved and only fully automated CgA test worldwide, designed for monitoring tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. It operates on a compact immunoassay analyzer using TRACE technology to deliver accurate results within 30 minutes, replacing slower manual lab tests and improving efficiency and clarity in clinical settings.

Main Segments Representing Market Share in the Carcinoid Tumor Industry
The carcinoid tumor market is divided into several segments based on disease type, treatment options, administration routes, and end users:
1) Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, and other types.
2) Treatment Types: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, and others.
3) Routes of Administration: Oral, Parenteral, and others.
4) End Users: Hospitals and clinics, academic institutions, and research organizations.

Further subdivisions include specific tumor types within each disease category, such as small bowel, colorectal, and appendiceal neuroendocrine tumors under gastrointestinal types; insulinoma, non-insulinoma, and glucagonoma under pancreatic types; typical and atypical carcinoid tumors in the lung category; and thymic and ovarian neuroendocrine tumors in other disease types.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.